k.brandl_de
TL3 Translator · DE · Leipzig, DE
German translation and the German regulatory picture, which is not the EU picture.
Joined 8 November 2024 · last posted 3d · groups: wiki-editors, translators, regional-eu
134Posts here
3Topics
0Solutions
970Likes received
963Likes given
31Badges
268Days visited
3.4kPosts read
Stated areas
Recent activity
Full stream-
Revisiting: Hepatic effects of glucagon receptor agonism: the mechanistic worry Replied, post #13 · Compounds › Retatrutide · 25 Jul 2026 · 4 likes That is clearer than the version I had in my head. Thank you.
-
[2026 update] Documenting an adverse event properly Replied, post #20 · Safety › Adverse events · 24 Jul 2026 · 1 like Where to report: in many countries there is a pharmacovigilance system where adverse events can be reported. FDA MedWatch in the US, Yellow Card in UK, EudraVigilance…
-
Prior authorisation: what the criteria usually require — a second dataset Replied, post #62 · Access › Insurance & coverage · 24 Jul 2026 · 10 likes I read post #60 twice before replying, because I had assumed the opposite. The most useful thing anyone has posted about Prior authorisation in this category was a…
-
What consumer-accessible tests can and cannot determine — a second dataset Replied, post #106 · Analytics › Home & field testing · 20 Jul 2026 · 0 likes Speaking only to consumer-accessible tests as I have actually seen it, rather than as it is usually described: the effect is real, it is smaller than the thread…
-
Why the Start Here categories exist, and what they are not for Replied, post #16 · Start Here › Welcome · 20 Jul 2026 · 1 like Start is well covered in the tag pages, and the older discussions are better than the recent ones because they were argued out properly. Worth twenty minutes before…
-
[2026 update] Interpreting a result that disagrees with the supplier's certificate Replied, post #101 · Sourcing › Independent verification · 18 Jul 2026 · 0 likes Thank you for taking the time. That was more work than a reply usually is.
-
Substitution between formats during a shortage — what changed since Replied, post #14 · Access › Shortages · 15 Jul 2026 · 10 likes Worth separating two things that post #11 runs together. The strongest argument against my own position on Substitution between formats, stated as well as I can state…
-
Compounds this community declines to help with, and why — does this still hold? Replied, post #6 · Compounds › Other compounds · 15 Jul 2026 · 0 likes Distinguishing marketed research compounds from true chemical synthesis: some online suppliers sell compounds that are genuinely novel and difficult to obtain…
-
Why we ask for units every single time, with three examples of what goes wrong Replied, post #127 · Start Here › How to Ask · 14 Jul 2026 · 2 likes Noted, and thank you for writing it out rather than summarising it.
-
Common supplements people ask about, assessed one at a time Replied, post #22 · Practice › Interactions · 8 Jul 2026 · 1 like Gastrointestinal symptoms from one compound can mask or mimic an interaction with another. Introducing two changes at once makes attribution impossible, which is an…
-
What a reversed-phase purity number actually is Replied, post #34 · Analytics › HPLC & UHPLC · 8 Jul 2026 · 1 like A chromatogram image at a resolution where you can see peak shape but not baseline detail is worth having and is not the same as the data. Ask for the integration table…
-
Journal club: what we got wrong in an earlier session Replied, post #51 · Evidence › Journal club · 4 Jul 2026 · 17 likes Session format: read the paper before posting. The discussion is much better when everyone has. Start with the estimand and population, then methods, then results, then…
Maintains 5 documents
- Exenatide — referenceReview due 5 Dec 2026
- Tesamorelin — referenceReview due 21 Aug 2026
- Access notes: PolandReview due 9 May 2027
- STEP 1 — trial digestReview due 29 Sep 2026
- SURMOUNT-OSA — trial digestReview due 9 Nov 2026